STAR

Across TCGA pan-cancer cohorts, STAR Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STAR data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher STAR Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated STAR expression acts as an unfavorable survival marker.

BLCA, KIRC, and LIHC are the cancer types where STAR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.077	0.476	<.001	33	view →
KIRC	DFS	Median	All	0.180	0.796	.001	24	view →
LIHC	DFS	Median	All	0.075	0.555	<.001	6	view →
LGG	OS	Median	All	0.610	0.896	.020	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUAD	OS	Median	All	0.176	0.670	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STAR–BLCA (DFS)

Open the BLCA breakdown →